Kieser Brian Joseph 的 Form 4 申報
Nexgel, Inc.NXGL,2026/11/13 申報
- 申報編號
- 0001493152-26-051920
- 申報時間
- 2026/11/13 21:59 ET
- 交易日
- 2026/11/10
- 申報延遲
- 3 天
- 10b5-1 計畫
- 沒有勾選
這份申報列了 1 筆非衍生性交易、9 筆衍生性交易。交易後 3 天申報。
申報人
一份 Form 4 可以有好幾位申報人,例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Kieser Brian JosephCIK 0002133654 | 董事、高階主管(代理執行長)、持股 10% 以上大股東 |
非衍生性證券(表 I)
普通股等股票的取得與處分,每一列是申報上的一筆。
| 交易日 | 證券 | 交易 | 股數 | 價格 | 金額 | 交易後持股 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2026/11/10 | Common Stock | P買進取得 | +133,216 | $5.50F1 | +$732,688 | 133,216 | 間接 | 價格異常 |
衍生性證券(表 II)
選擇權、認股權證、限制型股票單位等。股數是標的股票的股數;單價與金額是衍生證券本身的價格,交易後持有是衍生證券的單位數。
| 交易日 | 證券 | 交易 | 標的股數 | 單價 | 金額 | 交易後持有 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2026/11/10 | Common Stock | P買進取得 | +133,216 | $0.00F1 | $0 | 133,216 | 間接 | |
| 2026/11/10 | Common Stock | D交回公司取得 | +83,334 | –F3 | – | 0 | 直接 | |
| 2026/11/10 | Common Stock | A公司授予取得 | +181,819 | –F3 | – | 181,819 | 直接 | |
| 2026/11/10 | Common Stock | D交回公司取得 | +41,667 | –F3 | – | 0 | 直接 | |
| 2026/11/10 | Common Stock | A公司授予取得 | +41,667 | –F3 | – | 41,667 | 直接 | |
| 2026/11/10 | Common Stock | D交回公司取得 | +458,334 | –F3 | – | 0 | 間接 | |
| 2026/11/10 | Common Stock | A公司授予取得 | +1,000,000 | –F3 | – | 1,000,000 | 間接 | |
| 2026/11/10 | Common Stock | D交回公司取得 | +229,167 | –F3 | – | 0 | 間接 | |
| 2026/11/10 | Common Stock | A公司授予取得 | +229,167 | –F3 | – | 229,167 | 間接 |
附註與備註
本站收錄交易價格引用的附註、修正申報(Form 4/A)的全部附註,以及申報的備註。其他附註,例如間接持有的方式、交易計畫的細節,請看 SEC EDGAR 上的原文。
- F1
Reflects the purchase by Sequence LifeScience, Inc. ("Sequence") on November 10, 2026 of 133,216 units from the Issuer, each unit consisting of one share of Common Stock and a warrant to purchase one share of Common Stock (the "PIPE Warrant"), at $5.50 per unit, in a private placement under a Securities Purchase Agreement. No separate consideration was paid for the PIPE Warrant. The closing occurred on November 10, 2026. The PIPE Warrant has an original issue date of November 10, 2026, is exercisable for cash at $10.00 per share, and expires on the fifth anniversary of its original issue date. The Issuer has waived the beneficial-ownership limitation that would otherwise apply to these securities.
表 I 有 1 筆、表 II 有 1 筆交易的價格引用這則附註。
- F3
On November 10, 2026, the Reporting Person and Sequence entered into Note Amendment and Conversion Agreements with the Issuer that, among other things, reduced the conversion price of each Convertible Promissory Note from $12.00 to $5.50 per share and the exercise price of each Existing Warrant from $16.00 to $13.00 per share. The amendments are reported as the disposition of the original derivative security and the acquisition of the amended derivative security. The original securities are treated as disposed of solely for purposes of this Form 4 reporting; they were amended and remain outstanding as amended. The transactions were approved in advance by the Issuer's Board of Directors on November 10, 2026 for purposes of Rule 16b-3(d) and (e). Share amounts reflect the 1-for-20 reverse stock split effective October 12, 2026. The Note and Existing Warrant held directly were issued on May 11, 2026, and those held by Sequence were issued on April 17, 2026.
表 II 有 8 筆交易的價格引用這則附註。